Pharmacological Properties

Metaflam Oral Suspension belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs), formulated as a liquid suspension for convenient and accurate dosing in veterinary patients.

The active ingredient meloxicam exhibits potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) properties. Its therapeutic action is mediated primarily through the selective inhibition of cyclooxygenase-2 (COX-2), resulting in reduced synthesis of prostaglandins — the chemical mediators directly involved in inflammation, pain signaling, and fever response. This preferential COX-2 selectivity helps provide effective pain control while offering a more favorable gastrointestinal safety profile compared to non-selective NSAIDs, making Metaflam Oral Suspension a widely trusted veterinary analgesic.

After oral administration, meloxicam is rapidly and well absorbed from the gastrointestinal tract, achieving peak plasma concentrations within several hours. The drug is extensively bound to plasma proteins (approximately 97%), metabolized mainly in the liver through oxidative biotransformation, and excreted primarily via feces and urine in roughly equal proportions. The pharmacokinetic profile supports once-daily maintenance dosing for sustained pain relief.

Indications for Use

Metaflam Oral Suspension is indicated for the relief of inflammation and pain associated with acute and chronic musculoskeletal disorders in dogs, including osteoarthritis (degenerative joint disease), hip dysplasia, spondylosis, and other painful joint conditions. It is also prescribed for the control of postoperative pain and inflammation following orthopedic and soft tissue surgical procedures.

This veterinary NSAID suspension is intended for use in dogs and other species as specified by the manufacturer. The liquid formulation allows for precise weight-based dosing and is particularly convenient for small dogs or patients that have difficulty swallowing tablets. Buy Metaflam Oral Suspension online for flexible, accurate canine pain management.

Contraindications

Do not use Metaflam Oral Suspension in animals with known hypersensitivity to meloxicam or other NSAIDs. This veterinary anti-inflammatory is contraindicated in dogs with active gastrointestinal ulcers or bleeding, severe hepatic (liver) impairment, renal (kidney) insufficiency, cardiac disease, dehydration, hypovolemia, or hypotension. These conditions significantly increase the risk of serious NSAID-related adverse effects.

Metaflam Oral Suspension is not recommended for use in young puppies below the minimum age specified by the manufacturer or in pregnant and lactating animals unless the treating veterinarian has determined that the benefits outweigh the potential risks and the animal is maintained under close veterinary supervision throughout the treatment period.

Dosage and Method of Administration

Administer Metaflam Oral Suspension orally, either directly into the mouth via the calibrated dosing syringe provided, or mixed with food or a small amount of drinking water. The liquid formulation ensures accurate dosing based on body weight and allows easy dose adjustments.

The initial loading dose is typically 0.2 mg/kg on the first day of treatment, followed by a maintenance dose of 0.1 mg/kg once daily thereafter. The exact dosage should be determined based on the animal's body weight and the veterinarian's clinical recommendation. Do not exceed the prescribed dose or duration of treatment. Shake the bottle well before each use. Ensure continuous access to fresh drinking water during treatment.

Adverse Reactions

In rare cases, adverse reactions such as vomiting, diarrhea, soft stools, loss of appetite, and lethargy may occur, particularly at the initiation of therapy or if dosing recommendations are exceeded.

Very rarely, more serious adverse effects including gastrointestinal ulceration or hemorrhage, renal impairment, hepatic dysfunction, or hypersensitivity reactions may develop. If any adverse reactions are observed — especially dark or tarry stools, persistent vomiting, or marked behavioral changes — discontinue use immediately and consult a veterinarian without delay.

Overdose

Symptoms of meloxicam overdose may include gastrointestinal disturbances (vomiting, diarrhea, GI bleeding), depression, lethargy, and signs of renal dysfunction (increased thirst, abnormal urination patterns). In case of suspected overdose, initiate symptomatic and supportive treatment promptly under veterinary supervision. There is no specific antidote. Gastrointestinal protectants and intravenous fluid therapy may be necessary.

Special Warnings and Precautions

Do not administer Metaflam Oral Suspension concurrently with other NSAIDs or glucocorticoids (corticosteroids), as combination use dramatically increases the risk of gastrointestinal toxicity and ulceration. Ensure adequate hydration at all times during treatment by providing constant access to fresh water. Use with particular caution in elderly, debilitated, or medically compromised animals, as these patients may have increased susceptibility to NSAID-related adverse effects. Veterinary supervision and regular clinical monitoring are strongly recommended during prolonged use, including periodic blood work to assess renal and hepatic function.

Disclaimer

This product is intended for use in animals only. Always follow the advice and instructions of a licensed veterinarian. The information provided here is for general guidance and does not replace professional veterinary consultation. Use only as directed. The manufacturer and distributor are not responsible for any adverse effects resulting from misuse, overdose, or off-label use of this product. Keep out of reach of children and animals other than those for which the product is intended. In case of accidental ingestion by humans, seek medical attention immediately.